RE:Some speculative thoughts
lscfa wrote: At one time SBM had 3 different skin lightening candidates: the one licensed to Valeant's Obagi, 1067 and a third one as well. I never got a satisfactory answer from mgmt as to why three. If one is superior to the other two who wants to license the other two? Made no sense.
Mgmt said in recent videos that it was working with Valeant to reformulate the skin-lightening drug licensed to Obagi to make it more comparable to 1067. Why would Valeant even consider this? Why not just dump the inferior ligthener and buy 1067 and be done with it.
The delays SBM is having in closing a deal may be because the potential deal is with Valeant who is busy dealing with a mountain of debt and selling business off to rationize its operations. It would not surprise me to learn that SBM gave Valeant a right of first refusal to buy 1067 and are now caught up in Valeant's timetable.
This is definitely speculative. Especially since there are no further plans about Obagis future within Valeant group. As per
Bloomberg News as per June 2016, Valeant plans to sell it's dermatology assets including Obagi and Solta Medical. From this point of view, negotiation with Valeant wouldn't make any sense.
But time will tell and maybe Joe Papa meanwhile changed his mind.